Immunomedics Announces Presentations at the 2013 Annual Meeting of the American Association for Cancer Research

Immunomedics Announces Presentations at the 2013 Annual Meeting of the
American Association for Cancer Research

MORRIS PLAINS, N.J., April 1, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
(Nasdaq:IMMU), a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today announced that six
posters will be presented at the 2013 Annual Meeting of the American
Association for Cancer Research to be held in Washington, DC, from April 6 –
10, 2013.

The schedule and meeting places for the poster sessions, together with the
abstract number, poster section and poster board numbers, are listed below:

  o"MAb-PAM4 can differentiate between pancreatic ductal adenocarcinoma and
    chronic pancreatitis" [Abstract No. 1141, Session Title: Biomarkers 2:
    Gastrointestinal Cancers, Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall
    A-C, Poster Section 1, Poster Board Number 3]
    
  o"Targeting interferon-Lambda 1 with a stabilized dimer of anti-tumor Fab"
    [Abstract No. 1221, Session Title: Cytokines, Modification of the Tumor
    Microenvironment, and Intervention, Monday, April 8, 1:00 p.m. – 5:00
    p.m., Hall A-C, Poster Section 5, Poster Board Number 1]
    
  o"Cell-cell fusion in vivo transfers genes for human malignancy,
    metastasis, and the donor tumors' organoid phenotype to stromal hamster
    cells" [Abstract No. 1630, Session Title: Tumor-Stromal Interactions,
    Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall A-C, Poster Section 21,
    Poster Board Number 8]
    
  o"A Phase I study of IMMU-130 (labetuzumab-SN-38) anti-CEACAM5
    antibody-drug conjugate (ADC) in patients with metastatic colorectal
    cancer (mCRC)" [Abstract No. LB-159, Session Title: Late-Breaking
    Research: Clinical Trials, Tuesday, April 9, 8:00 a.m. – 12:00 p.m., Hall
    A-C, Poster Section 47]
    
  o"CD22-targeting epratuzumab mediates trogocytosis of multiple cell-surface
    markers on normal, malignant, and lupus B cells" [Abstract No. 4744,
    Session Title: Immune Therapeutics and Monoclonal Antibodies 2, Wednesday,
    April 10, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 5, Poster Board
    Number 13]
    
  o"Novel T-cell redirecting trivalent bispecific antibodies" [Abstract No.
    4747, Session Title: Immune Therapeutics and Monoclonal Antibodies 2,
    Wednesday, April 10, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 5,
    Poster Board Number 16]

Cynthia L. Sullivan, President and CEO, commented: "Our presentations
represent a diverse set of products and technologies for the therapy of
hematological and solid cancers, including our elucidation of the possible
mechanism of action of epratuzumab in the therapy of system lupus
erythematosus. The late-breaking poster on our IMMU-130 product candidate will
present our first clinical results with this novel antibody-drug conjugate in
patients with advanced, relapsed, metastatic colorectal cancers from our
ongoing Phase I dose-escalation trial."

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused
on the development of monoclonal antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases.We have developed
a number of advanced proprietary technologies that allow us to create
humanized antibodies that can be used either alone in unlabeled or "naked"
form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or
toxins, in each case to create highly targeted agents.Using these
technologies, we have built a pipeline of therapeutic product candidates that
utilize several different mechanisms of action.We also have a majority
ownership in IBC Pharmaceuticals, Inc., which is developing a novel
DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and
multifunctional antibodies, and a new method of delivering imaging and
therapeutic agents selectively to disease, especially different solid cancers
(colorectal, lung, pancreas, etc.), by proprietary, antibody-based,
pretargeting methods. We believe that our portfolio of intellectual property,
which includes approximately 219 active patents in the United States and more
than 400 foreign patents, protects our product candidates and technologies.
For additional information on us, please visit our website at
www.immunomedics.com. The information on our website does not, however, form a
part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials, out-licensing arrangements (including the timing and amount of
contingent payments), forecasts of future operating results, potential
collaborations, and capital raising activities, involve significant risks and
uncertainties and actual results could differ materially from those expressed
or implied herein. Factors that could cause such differences include, but are
not limited to, risks associated with any cash payment that the Company might
receive in connection with a sublicense involving a third party and UCB, which
is not within the Company's control, new product development (including
clinical trials outcome and regulatory requirements/actions), our dependence
on our licensing partners for the further development of epratuzumab and
veltuzumab for non-cancer indications, competitive risks to marketed products
and availability of required financing and other sources of funds on
acceptable terms, if at all, as well as the risks discussed in the Company's
filings with the Securities and Exchange Commission.The Company is not under
any obligation, and the Company expressly disclaims any obligation, to update
or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
         ccheng@immunomedics.com
 
Press spacebar to pause and continue. Press esc to stop.